About Bruce Halpryn
Bruce Halpryn is a chairman and chief executive officer at Eikonoklastes Therapeutics.
Bruce Halpryn first appears on SEC filings in 2020.
Experience
This experience comes from Bruce Halpryn's profile and from SEC filings. For roles taken from filings, the years are when the filings name Bruce Halpryn in the role, so the role may have started earlier or lasted longer.
Eikonoklastes Therapeutics, Inc. Current
Chairman and Chief Executive Officer
Cofounder, Chief Executive Officer and President (2019 – Present)
2019 – Present · Cincinnati, OH
Develops gene therapies for people with ALS and other neurodegenerative diseases.
MB
Miami City Ballet Current
Board of Directors, Chair of School Committee, Finance and Personnel + Compensation Committees
2019 – Present
FC
FotoFocus Cincinnati Current
Board Of Directors, former President of Board
2014 – Present
CB
Cincinnati Ballet Current
Board member, former chair artistic and marketing committees
2012 – Present
MI
Myonexus Therapeutics, Inc.
Chief Operating Officer
2016 – 2019
LI
Larta Institute
Senior Advisor, Life Sciences and Open Innovation
2007 – 2019
KM
Kinnear Pharmaceuticals (formerly N8 Medical)
Chief Operating Officer
2014 – 2017
CN
concert:nova
President, Board of Directors
2013 – 2017
4L
4iNNO, LLC
Director, Technology Practice
2012 – 2014
PC
P&G Global Health Care
Sr. Dir., New Bus. Dev.: IP & Tech. Due Diligence, IP Mngmnt, Core Science, Tech. Dev., Compet. Inte
2009 – 2012
PP
P&G Pharmaceuticals (formerly Norwich Eaton Pharmaceuticals)
Director Connect & Develop (Open Innovation)/IP Management and Technical Due Diligence (2005 – 2009)
Director, Early Phase Drug Development (1995 – 2005)
1995 – 2009
PE
Procter & Gamble Pharmaceuticals EU
Special assignment, Director of European Subsidiaries Regulatory Affairs (1994 – 1995)
Associate Director, Cardiac Drug Development/Project leader congestive heart failure development pro (1990 – 1995)
1990 – 1995
NP
Norwich Eaton Pharmaceuticals
Staff Scientist
1986 – 1990
NC
NASA Ames Research Center
Spaceflight Cardiovacular Deconditioning Research Scientist
1979 – 1986
Key Colleagues at Startups
The people Bruce Halpryn works with at each company, as listed on that company's latest Form D.
Eikonoklastes Therapeutics, Inc. · Form D/A, Oct 6, 2026
SL
Samuel Lee
President and Chief Business Officer, director
KM
Kenneth Morand
Partner, CincyTech and director
TF
Thomas Finn
Director
RJ
Robert Johnson
CEO, Kesmalea Therapeutics and director
JN
Joseph Nolan
CEO, Jaguar Gene Therapy and director